Tg Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Vanguard Portfolio Management has reported beneficial ownership of 5.26% of TG Therapeutics Inc.'s common stock as of March 31, 2026.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in TG Therapeutics Inc. following an internal realignment.
NASDAQ
State Street Corporation has reported a 5.1% beneficial ownership stake in TG Therapeutics Inc., totaling 8,100,619 shares of common stock.
NASDAQ
State Street Corporation has reported a 4.7% beneficial ownership stake in TG Therapeutics Inc., held for investment purposes without intent to influence control.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 12.8% Passive Stake in TG Therapeutics
BlackRock, Inc. has filed an updated Schedule 13G, revealing a 12.8% beneficial ownership stake in TG Therapeutics, Inc. as of March 31, 2025.
NASDAQ
The Vanguard Group has reported a 10.01% beneficial ownership stake in TG Therapeutics Inc, holding 15,596,480 shares as of December 31, 2024, for passive investment purposes.